Betta Pharmaceuticals Co., Ltd.: all 100 studies

Page 1 of 1. Open to participants first (22), then studies with results posted, then the rest; newest registration first within each.

• Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants.RecruitingNCT07809815Phase 1
• Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic ImpairmentRecruitingNCT07809802Phase 1
• Drug-Drug Interaction Study of Vorolanib Tablets in Healthy ParticipantsRecruitingNCT07809789Phase 1
• Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung CancerRecruitingNCT07806604
• Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.RecruitingNCT07448116Phase 1/2
• Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingNCT07435038Phase 1/2
• Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKIRecruitingNCT07181499Phase 2
• Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruitingNCT06885840Phase 2
• A Phase I Study of CFT8919 in Patients With Advanced NSCLCRecruitingNCT06641609Phase 1
• A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy VolunteersNot yet recruitingNCT06492525Phase 1
• Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsRecruitingNCT06041776Phase 3
• Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationNot yet recruitingNCT06015568Phase 1
• BPB-101 in Subjects With Metastatic or Locally Advanced Solid TumorsRecruitingNCT05869240Phase 1/2
• A Study of BPI-452080 in Subjects With Solid TumorsNot yet recruitingNCT05843305Phase 1
• A Study of BPI-460372 in Advanced Solid Tumor PatientsRecruitingNCT05789602Phase 1
• BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT05393466Phase 1/2
• Phase 1 Study of BPI-442096 in Advanced Solid Tumor PatientsNot yet recruitingNCT05369312Phase 1
• Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingNCT05341583Phase 3
• A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory LymphomaRecruitingNCT05341557Phase 1
• Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Phase 1/2
• Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALRecruitingNCT04872478Phase 1
• Expanded Access to Ensartinib for Participants With ALK+ NSCLCAvailableNCT04146571
• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedNCT01625234Phase 1/2Results posted
• Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Phase 3Results posted
• A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted ConditionsCompletedNCT05665283Phase 1
• A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerActive, not recruitingNCT05433480Phase 3
• A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668Status unknownNCT05341570Phase 1
• A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsStatus unknownNCT05329298Phase 1/2
• A Food-Effect Study of BPI-16350 in Healthy SubjectsCompletedNCT05316259Phase 1
• A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid TumorsStatus unknownNCT05315180Phase 1
• A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid TumorsStatus unknownNCT05302843Phase 1
• Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingNCT05007938Phase 2
• A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04946890Phase 1/2
• The Absorption, Metabolism and Excretion of [14C]D-0316 in HumanStatus unknownNCT04464551Phase 1
• The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedNCT04434326Phase 1
• X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesStatus unknownNCT04415320Phase 2
• Bioequivalency Study of CM082 Tablet in Healthy VolunteersCompletedNCT04328506Phase 1
• CM082 in Patients With Myopic Choroidal Neovascularization (CNV)SuspendedNCT04222842Phase 1
• D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedNCT04206072Phase 2/3
• A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy VolunteersCompletedNCT04126668Phase 1
• A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation TherapyStatus unknownNCT04058704Phase 3
• CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
• CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
• The Absorption, Metabolism and Excretion of [14C]Ensartinib in HumanStatus unknownNCT03804541Phase 1
• Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03792958Phase 1
• A Phase I Study of BPI-16350 in Patients with Advanced Solid TumorActive, not recruitingNCT03791112Phase 1
• Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR MutationStatus unknownNCT03754530Phase 2
• Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerStatus unknownNCT03749213Phase 2
• Safety and Tolerability of Oral CM082 in Patients With wAMDStatus unknownNCT03710863Phase 2
• X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene RearrangementStatus unknownNCT03608007Phase 2
• Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.Status unknownNCT03602547Phase 2
• Bioequivalency Study of Ensartinib Capsules in Healthy VolunteersCompletedNCT03536481Phase 1
• A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.CompletedNCT03510611Phase 1
• Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsCompletedNCT03510104Phase 1
• Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung CancerStatus unknownNCT03396185Phase 2
• Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung CancerStatus unknownNCT03349203Phase 2
• Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung CancerStatus unknownNCT03346811Phase 2
• Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric CancerStatus unknownNCT03286244Phase 1
• Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisTerminatedNCT03222622Phase 2
• X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibActive, not recruitingNCT03215693Phase 2
• Dose Escalating Study of BPI-3016 in Healthy SubjectsStatus unknownNCT03188848Phase 1
• CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3
• Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
• Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLCStatus unknownNCT02929290Phase 1
• Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsCompletedNCT02914990Phase 1
• Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisCompletedNCT02801435Phase 1
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3
• High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain MetastasesStatus unknownNCT02726568Phase 2
• Study of the Combination of CM082 With Everolimus in Patients With mRCCStatus unknownNCT02577458Phase 1
• Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis PatientsCompletedNCT02574091Phase 1
• Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic LeukemiaCompletedNCT02544789Phase 2
• Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With ChemotherapyCompletedNCT02486354Phase 3
• Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid TumorsCompletedNCT02478866Phase 1
• Phase 1 Study of CM082 in Patients With wAMDSuspendedNCT02452385Phase 1
• Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Phase 3
• High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon MutationStatus unknownNCT02404675Phase 4
• A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal CarcinomaStatus unknownNCT02328261Phase 2
• Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02278458Phase 1
• Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Phase 2
• Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLCStatus unknownNCT02194556Phase 4
• Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung AdenocarcinomaStatus unknownNCT02125240Phase 3
• Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaStatus unknownNCT02103257Phase 4
• Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIStatus unknownNCT02066870Phase 1
• Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic InsufficiencyStatus unknownNCT02062515Phase 2
• Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR MutationCompletedNCT02044328Phase 2
• High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseStatus unknownNCT02027090Phase 2
• Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02024633Phase 1
• Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR MutationStatus unknownNCT01929200Phase 2
• Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain MetastasesStatus unknownNCT01926171Phase 4
• Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in ChinaCompletedNCT01863485Phase 1
• Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISHCompletedNCT01855854Phase 2
• Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC PatientsStatus unknownNCT01843647Phase 2
• Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib TherapySuspendedNCT01720901Phase 4
• Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma PatientsCompletedNCT01719536Phase 3
• Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib TreatmentStatus unknownNCT01707329Phase 2
• Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable DiseaseStatus unknownNCT01690390Phase 2
• Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung AdenocarcinomaStatus unknownNCT01665417Phase 4
• First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated PatientsStatus unknownNCT01646450Phase 4
• Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR MutationCompletedNCT01516983Phase 1/2
• Dose Escalation Of Icotinib In Previously Treated Patients With Routine DoseCompletedNCT01465243Phase 4

← Betta Pharmaceuticals Co., Ltd. overview and focus areas